Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and 18F-FLT PET imaging

Karroum, Oussama;Mignion, Lionel;Kengen, Julie;Karmani, Linda;Jordan, Bénédicte;et.al.
(2013) Contrast Media & Molecular Imaging — Vol. 8, n° 3, p. 274-280 (2013)

Files

KARROUM2013.pdf
  • Open Access
  • Adobe PDF
  • 300.2 KB

Details

Authors
  • Karroum, OussamaUCLouvain
    Author
  • Author
  • Kengen, JulieUCLouvain
    Author
  • Karmani, LindaUCLouvain
    Author
  • Levêque, PhilippeUCLouvain
    Author
  • Danhier, Pierreorcid-logoUCLouvain
    Author
  • Magat, JulieUCLouvain
    Author
  • Bol, AnneUCLouvain
    Author
  • Labar, DanielUCLouvain
    Author
  • Grégoire, VincentUCLouvain
    Author
  • Author
  • Author
  • Author
  • Author
Show more
Abstract
The purpose of this study was to determine the value of different imaging modalities, that is, magnetic resonance imaging/spectroscopy (MRI/MRS) and positron emission tomography (PET), to assess early tumor response to sorafenib with or without radiotherapy. Diffusion-weighted (DW)-MRI, choline (1)H MRS at 11.7 T, and (18)F-FLT PET imaging were used to image fibrosarcoma (FSaII) tumor-bearing mice over time. The imaging markers were compared with apoptosis cell death and cell proliferation measurements assessed by histology. Anti-proliferative effects of sorafenib were evidenced by (1)H MRS and (18)F-FLT PET after 2 days of treatment with sorafenib, with no additional effect of the combination with radiation therapy, results that are in agreement with Ki67 staining. Apparent diffusion coefficient calculated using DW-MRI was not modified after 2 days of treatment with sorafenib, but showed significant increase 24 h after 2 days of sorafenib treatment combined with consecutive irradiation. The three imaging markers were able to show early tumor response as soon as 24 h after treatment initiation, with choline MRS and (18)F-FLT being sensitive to sorafenib in monotherapy as well as in combined therapy with irradiation, whereas DW-MRI was only sensitive to the combination of sorafenib with radiotherapy.
Affiliations

Citations

Karroum, O., Mignion, L., Kengen, J., Karmani, L., Levêque, P., Danhier, P., Magat, J., Bol, A., Labar, D., Grégoire, V., Bouzin, C., Feron, O., Gallez, B., & Jordan, B. (2013). Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and 18F-FLT PET imaging. Contrast Media & Molecular Imaging, 8(3), 274-280. https://doi.org/10.1002/cmmi.1525 (Original work published 2013)